|
The said unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets.
The previous EU – GMP inspection for this facility was in January 2020.
Earlier, the company’s unit 4, Jadcherla, Telangana, facility was inspected by AGES, Austria from 22 January, 2024 until 26 January, 2024.
Following a successful inspection, the said unit has been issued GMP Certification from Ages, Austria.
This inspection will facilitate continued supply of medicines for commercial distribution to various countries of the European Union from this unit.
Shilpa Medicare is a global brand in manufacturing and supplying of API and formulation globally in different regulated markets.
The company’s consolidated net profit stood at Rs 4.58 crore in Q3 FY24 as compared with net loss of Rs 6.62 crore posted in Q3 FY23. Net sales stood at Rs 286.48 crore in Q3 FY24, up 9.1% year on year.
The scrip rallied 6.14% to ends at Rs 540.45 on Tuesday, 16 April 2024. The domestic market is shut on account of Ram Navami.
|